{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:44:53Z","timestamp":1791999893164,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.dmd.2026.100349","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:34:51Z","timestamp":1782171291000},"page":"100349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A framework for optimized reaction phenotyping of the seven major hepatic P450 isoforms in human liver microsomes using six mechanism-based inactivators and one reversible inhibitor"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1186-6669","authenticated-orcid":false,"given":"Ting","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0561-5938","authenticated-orcid":false,"given":"Kevin","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klairynne","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0300-726X","authenticated-orcid":false,"given":"Mitchell E.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.dmd.2026.100349_bib1","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1021\/cr0307143","article-title":"Structure and chemistry of cytochrome P450","volume":"105","author":"Denisov","year":"2005","journal-title":"Chem Rev"},{"issue":"23","key":"10.1016\/j.dmd.2026.100349_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312808","article-title":"Cytochrome P450 enzymes and drug metabolism in humans","volume":"22","author":"Zhao","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.dmd.2026.100349_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1389450118666170125144557","article-title":"Cytochrome P450 structure, function and clinical significance: a review","volume":"19","author":"Manikandan","year":"2018","journal-title":"Curr Drug Targets"},{"issue":"6","key":"10.1016\/j.dmd.2026.100349_bib4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2174\/1389200023337054","article-title":"The CYTOCHROME P450 superfamily: biochemistry, evolution and drug metabolism in humans","volume":"3","author":"Danielson","year":"2002","journal-title":"Curr Drug Metab"},{"issue":"5","key":"10.1016\/j.dmd.2026.100349_bib5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/BF02353474","article-title":"The human drug metabolizing cytochromes P450","volume":"24","author":"Wrighton","year":"1996","journal-title":"J Pharmacokinet Biopharm"},{"issue":"3","key":"10.1016\/j.dmd.2026.100349_bib6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1517\/17425255.2014.876006","article-title":"The role of drug metabolizing enzymes in clearance","volume":"10","author":"Di","year":"2014","journal-title":"Expert Opin Drug Met"},{"issue":"2","key":"10.1016\/j.dmd.2026.100349_bib7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1208\/s12248-008-9037-4","article-title":"Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical","volume":"10","author":"Sinz","year":"2008","journal-title":"AAPS J"},{"issue":"13-14","key":"10.1016\/j.dmd.2026.100349_bib8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.drudis.2006.05.001","article-title":"Designing better drugs: predicting cytochrome P450 metabolism","volume":"11","author":"de Groot","year":"2006","journal-title":"Drug Discov Today"},{"issue":"5","key":"10.1016\/j.dmd.2026.100349_bib9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1568026013395001","article-title":"Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery","volume":"1","author":"Yan","year":"2001","journal-title":"Curr Top Med Chem"},{"issue":"3","key":"10.1016\/j.dmd.2026.100349_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/03602539508998329","article-title":"Clinical importance of hepatic cytochrome P450 in drug metabolism","volume":"27","author":"Spatzenegger","year":"1995","journal-title":"Drug Metab Rev"},{"issue":"4","key":"10.1016\/j.dmd.2026.100349_bib11","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bcp.12086","article-title":"Renal drug metabolism in humans: the potential for drug\u2013endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT)","volume":"76","author":"Knights","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100349_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/00003088-200746020-00003","article-title":"Pharmacokinetic drug interactions involving 17\u03b1-ethinylestradiol","volume":"46","author":"Zhang","year":"2007","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.dmd.2026.100349_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/00498254.2014.945196","article-title":"Chemical inhibitors of CYP450 enzymes in liver microsomes: combining selectivity and unbound fractions to guide selection of appropriate concentration in phenotyping assays","volume":"45","author":"Nirogi","year":"2015","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.dmd.2026.100349_bib14","doi-asserted-by":"crossref","first-page":"7.8.1","DOI":"10.1002\/cpph.9","article-title":"In vitro drug metabolism using liver microsomes","volume":"74","author":"Knights","year":"2016","journal-title":"Curr Protoc Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100349_bib15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/dmd.114.058750","article-title":"Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes","volume":"43","author":"Zientek","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"20","key":"10.1016\/j.dmd.2026.100349_bib16","doi-asserted-by":"crossref","first-page":"7407","DOI":"10.1021\/bi973011m","article-title":"Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate","volume":"37","author":"Racha","year":"1998","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.dmd.2026.100349_bib17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1124\/dmd.31.3.289","article-title":"Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine","volume":"31","author":"Bertelsen","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100349_bib18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1124\/jpet.103.056127","article-title":"Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine","volume":"308","author":"Richter","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.dmd.2026.100349_bib19","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1021\/jm300065h","article-title":"Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure\u2013activity relationships and discovery strategies to mitigate drug\u2013drug interaction risks","volume":"55","author":"Orr","year":"2012","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.dmd.2026.100349_bib20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/00498254.2024.2395557","article-title":"Mechanism-based inactivation of cytochromes P450: implications in drug interactions and pharmacotherapy","volume":"54","author":"Tan","year":"2024","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.dmd.2026.100349_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1124\/dmd.108.023358","article-title":"Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (\u00b1)-suprofen: a comparison of kinetics and probe substrate selection","volume":"37","author":"Hutzler","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100349_bib22","first-page":"305","article-title":"Cytochrome P450, Structure, Mechanism, and Biochemistry","author":"de Montellano","year":"2012","journal-title":"J Am Chem Soc"},{"issue":"1","key":"10.1016\/j.dmd.2026.100349_bib23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s002280050163","article-title":"Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine","volume":"51","author":"Jeppesen","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100349_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s002280100268","article-title":"Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine","volume":"57","author":"Giancarlo","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100349_bib25","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1124\/dmd.32.6.626","article-title":"Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro","volume":"32","author":"Turpeinen","year":"2004","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2026.100349_bib26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.clpt.2005.02.010","article-title":"Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation","volume":"77","author":"Turpeinen","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100349_bib27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.bcp.2004.10.008","article-title":"Inhibition of human CYP2B6 by N,N\u2032,N\u2033-triethylenethiophosphoramide is irreversible and mechanism-based","volume":"69","author":"Richter","year":"2005","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100349_bib28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/dmd.105.007633","article-title":"Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions","volume":"34","author":"Ogilvie","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2026.100349_bib29","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1124\/dmd.107.015883","article-title":"A comparison of 2-phenyl-2-(1-piperidinyl)propane (PPP), 1,1\u2032,1\u2033-phosphinothioylidynetrisaziridine (ThioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6","volume":"35","author":"Walsky","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2026.100349_bib30","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3109\/00498250903191427","article-title":"Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel","volume":"39","author":"Nishiya","year":"2009","journal-title":"Xenobiotica"},{"issue":"12","key":"10.1016\/j.dmd.2026.100349_bib31","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1124\/dmd.111.041947","article-title":"Studies to further investigate the inhibition of human liver microsomal CYP2C8 by the acyl-\u03b2-glucuronide of gemfibrozil","volume":"39","author":"Jenkins","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmd.2026.100349_bib32","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/bdd.2207","article-title":"Dasotraline as a selective cytochrome 2B6 inhibitor for reaction phenotyping","volume":"40","author":"Yang","year":"2019","journal-title":"Biopharm Drug Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2026.100349_bib33","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1124\/dmd.32.6.584","article-title":"Validation of (-)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes","volume":"32","author":"Cai","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100349_bib34","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0076-6879(95)49038-8","article-title":"Mechanism-based enzyme inactivators","volume":"249","author":"Silverman","year":"1995","journal-title":"Methods Enzym"},{"issue":"1","key":"10.1016\/j.dmd.2026.100349_bib35","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1021\/tx7002504","article-title":"Mechanism-based inactivation of human cytochromes P450s: experimental characterization, reactive intermediates, and clinical implications","volume":"21","author":"Hollenberg","year":"2008","journal-title":"Chem Res Toxicol"},{"issue":"11","key":"10.1016\/j.dmd.2026.100349_bib36","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0090-9556(24)14938-0","article-title":"Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes","volume":"27","author":"Obach","year":"1999","journal-title":"Drug Metabolism Dispos Biological Fate Chem"},{"issue":"6","key":"10.1016\/j.dmd.2026.100349_bib37","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/clpt.2014.50","article-title":"Fluoxetine- and norfluoxetine-mediated complex drug\u2013drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4","volume":"95","author":"Sager","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.dmd.2026.100349_bib38","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/dmd.120.000089","article-title":"(\u2013)-N-3-Benzylphenobarbital is superior to omeprazole and (+)-N-3-benzylnirvanol as a cyp2c19 inhibitor in suspended human hepatocytes","volume":"48","author":"Cuypers","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100349_bib39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/00498254.2017.1422156","article-title":"Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro SilensomesTM model","volume":"49","author":"Parmentier","year":"2019","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.dmd.2026.100349_bib40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/dmd.30.3.235","article-title":"(+)-N-3-benzyl-nirvanol and (\u2212)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19","volume":"30","author":"Suzuki","year":"2002","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:52:55Z","timestamp":1791996775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0090955626006185"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100349","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A framework for optimized reaction phenotyping of the seven major hepatic P450 isoforms in human liver microsomes using six mechanism-based inactivators and one reversible inhibitor","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100349","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100349"}}